## OPIOID/BENZODIAZEPINE/PAIN THERAPY PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

ONLY the provider may complete this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit https://www.bcbstx.com/provider/medicaid/pharmacy/star-kids-prior-authorization.

PATIENT AND INSURANCE INFOR Patient Name (First):			Last:			oday's Date:  M: DOB (mm/dd/yyyy):				
		Luoti	1							
Pat	ent Address:		City, State, Zip			Patient Telephone:				
BCBS ID Number:					Group Number:	Group Number:				
PRE	SCRIBER/CLINIC INFORM	IATION			· 					
Pre	scriber Name:	Prescr	Prescriber NPI#:		Specialty:		Contact Name:			
Clinic Name:		1	Clini		c Address:					
City, State, Zip:			Phon		e #:	Secure Fax #:				
PLE	ASE ATTACH ANY ADDIT	IONAL INFOR	MATION THAT S	SHOUL	D BE CONSIDERE	D WITH	THIS REQUEST			
Pat	ient's Diagnosis - ICD code	plus description	on:							
Ме	dication Requested:		Strength: Length of Therapy:							
Do	sing Schedule:			Qua	antity per Month:					
1.	Is the patient currently trea	ated with the re	quested medicati	ion?			Yes No			
	If yes, when was treatm	ent with the re	quested medicati	on star	ted?					
2.	Does the patient have a di	agnosis of chr	onic cancer pain	due to	an active malignanc	y?	Yes No			
3.	Is the patient eligible for ho	ospice or pallia	tive care?				Yes No			
4.	Is the requested medication	n a benzodiaz	epine that will be	taken	concurrently with an	opioid?	Yes No			
	If no, is the requested medication an opioid that will be taken concurrently with a benzodiazepine? Yes									
5.	•	•			-	•	I that apply)? ☐ Yes ☐ No			
	☐ Pain Specialist ☐ Neurologist ☐ Behavioral Health Specialist									
6.	<u> </u>		_	ued wit		-	Yes No			
	<b>If no</b> , please explain	n:								
	What is the requested duration of the concurrent use of the opioid and benzodiazepine?									
	Will the patient be monitored during the concurrent use of the opioid and benzodiazepine agents?									
7.	Is the benzodiazepine beir	ng used for a p	sychiatric diagno:	sis, mu	iscle spasms, or a c	onvulsive	e disorder? Yes No			
Please list all reasons for selecting the requested <b>medication</b> , <b>dosing schedule</b> , <b>and quant</b>										
	contraindications, allergies or history of adverse drug reactions to alternatives, lower dose tried).									
					· 					
9.	Dlease list any other media	cations or non-	nharmacological	theran	ies the nationt will us	se in <b>con</b>	nbination with the requested			
٥.	medication for treatment of			•	•		ioniadon with the requested			
		Qı	uantity:	_			Quantity:			
		Qı	ıantity:	_	Quantity:					
					Quantity:					

6801 TXSK OBPT 0422 Page **1** of **2** 

Patie	ent Name (First):	Last:		M:	DOB (mm/dd/yyyy):					
10.	10. Please list all medications the patient has <b>previously tried and failed for treatment of this diagnosis.</b> (Please specify if									
	the patient has tried brand-name products, generic products, or over-the-counter products.)									
		Date(s):		Date(s):						
		Date(s):								
		Date(s):			Date(s):					
11. Please list all non-pharmacological therapy the patient has previously tried and failed for treatment of this										
Prescriber or Authorized Signature: Date:										
Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information										
regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and										
complete and the requested services are medically indicated and necessary to the health of the patient.  Note: Payment is subject to member eligibility. Authorization does not guarantee payment.										
Please fax or mail this form to:			CONFIDENTIALITY NOTICE: This communication is intended only for the							
Prime Therapeutics LLC, Clinical Review Department 2900 Ames Crossing Road			use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message							
Eagan, Minnesota 55121			is not the intended recipient, you are hereby notified that any							
					ing of this communication is strictly					
TOLL FREE			prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 866.202.3474 and return the							
Fax: 877.243.6930 Phone: 855.457.1200			original message to Prime TI		eutics via U.S. Mail. Thank you for your					
			cooperation.							

6801 TXSK OBPT 0422 Page **2** of **2**